Sareum is a drug discovery company, headquartered in Cambridge UK, that produces targeted small molecule therapeutics, focusing on cancer and auto-immune disease. Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.
Sareum’s Chk1 kinase cancer research programme is a joint research collaboration with The Institute of Cancer Research and Cancer Research Technology Limited. The development candidate resulting from the collaboration increases the effectiveness of current cancer therapeutics in several in-vivo cancer models.
SKIL® (Sareum Kinase Inhibitor Library) is Sareum’s drug discovery technology platform that has so far produced the Company’s Aurora, VEGFR-3, ALK, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL can also generate drug research programmes against other kinase targets.
Sareum Holdings plc is listed on the AIM market of the London Stock Exchange and trades under the symbol SAR.
Specialties
cancer research, oncology, drug discovery, auto-immune disease
Sareum Ltd Activity on LinkedIn
-
Sareum Ltd Interim results & research update will be announced on Feb 27 -
Sareum Ltd Updated research note from Hybridan Research -
Sareum Ltd New J Med Chem paper from Sareum / ICR - Structure-Guided Evolution of Potent and Selective CHK1 Inhibitors through Scaffold Morphing